United Therapeutics CorpChange company Symbol lookupSelect an option...UTHR United Therapeutics CorpEMUSF Electric Metals USA LtdINPX InpixonHUBC Hub Cyber Security LtdPTON Peloton Interactive IncPIXY ShiftPixy IncBCAN BYND Cannasoft Enterprises IncGLTO Galecto IncERNA Eterna Therapeutics IncTANH Tantech Holdings LtdGo
United Therapeutics Corporation is a pharmaceutical company. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Tyvaso (treprostinil) Inhalation Solution (Tyvaso), which includes the Tyvaso Inhalation System; Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso and Tyvaso DPI are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin), which is approved for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKinds Afrezza (insulin human) Inhalation Powder product.
|
|
|
|
| |
Company Profile
United Therapeutics Corporation is a pharmaceutical company. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Tyvaso (treprostinil) Inhalation Solution (Tyvaso), which includes the Tyvaso Inhalation System; Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso and Tyvaso DPI are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin), which is approved for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKinds Afrezza (insulin human) Inhalation Powder product.
Valuation Ratios
- Price/Earnings (TTM)
- 13.00x
- Price/Sales (TTM)
- 5.11x
- Price/Book (MRQ)
- 1.99x
- Price/Cash Flow (TTM)
- 11.68x
MRQ = Most Recent Quarter
Price Performance
Financial Statements
Balance sheet
Values displayed are in millions.
Income statement
Values displayed are in millions.
Cash flow
Values displayed are in millions.
Company Officers
- Martine A. RothblattChmn.
- Michael BenkowitzPres.
- Christopher Patusky
- James C. EdgemondCFO
- Paul A. MahonExec.VP
Address
- 1000 Spring St
- Silver Spring, MD 20910
- Phone: (301) 608-9292
- Fax: (301) 608-9291
- https://www.unither.com/
Insider Trading
During the most recent quarter, 285K shares were sold in insider trading.
Insider trading information report provided by Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.